Alzheimer's Boom or Bust EconRx

Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.
email: econrxpodcast@gmail.com
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx
Website: https://econrx.libsyn.com/